In the era of immuno‐oncology, inhibitors of programmed cell death 1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) have provided robust survival benefits for patients with locally advanced and metastatic non‐small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and lung cancer.